Table 1.

Total and percentage use of diabetes medications in treated diabetes visits by age, 2014–2015

Treatment	Age 30–64 y		Age ≥ 65 y		P-valuea	Most common medicationb
	Visits, 100 000 (95% Cl)	Visits, % (95% Cl)	Visits, 100 000 (95% Cl)	Visits, % (95% Cl)
Metformin	141.0 (117.5–164.6)	70.0 (64.1–75.4)	130.4 (107.5–153.3)	56.0 (50.1–61.7)	<.001	Metformin
Any sulfonylurea	58.2 (43.5–73.1)	28.9 (23.6–34.9)	75.8 (62.0–89.7)	32.6 (27.7–37.9)	.39	Glipizide
Long-acting sulfonylureasc	19.9 (9.8–29.9)	9.9 (6.3–15.1)	15.1 (10.5–19.6)	6.5 (4.9–8.5)	.13	Glyburide
Thiazolidinediones	9.3 (5.1–13.5)	4.6 (3.0–7.1)	9.3 (5.3–13.3)	4.0 (2.6–6.1)	.59	Pioglitazone
DPP-4 inhibitors	33.0 (22.7–43.3)	16.3 (12.8–20.7)	39.7 (28.5–51.0)	17.1 (13.9–20.7)	.82	Sitagliptin
GLP-1 receptor agonists	12.5 (6.9–18.1)	6.2 (4.1–9.1)	6.8 (2.5–11.0)d	2.9 (1.6–5.4)d	.004	Liraglutide
SGLT-2 inhibitors	14.6 (5.9–23.3)	7.2 (4.3–12.0)	e	e		Canagliflozin
Any insulin	66.4 (48.7–84.1)	33.0 (26.9–39.6)	90.7 (68.1–113.3)	39.0 (34.2–43.9)	.11	Insulin glargine
Long-acting insulin	45.1 (30.9–59.2)	22.4 (17.3–28.5)	70.3 (48.8–91.9)	30.2 (25.0–35.9)	.017	Insulin glargine
Rapid-acting insulin	21.7 (11.2–32.2)	10.8 (7.1–16.0)	21.3 (14.5–28.1)	9.1 (7.1–11.7)	.51	Insulin aspart

Data are average number of treated diabetes visits per year in 100 000s or percentage of treated diabetes visits in the designated age category. Combination products contributed to each medication class in the combination.

^aComparing age categories by survey-weighted Pearson χ² test.

^bThe generic name of the most common medication in each class is shown. These are the same for both age categories.

^cPredominantly glyburide, <1% chlorpropamide.

^dEstimated based on 90 unweighted visits with relative standard error of 32%.

^eToo few visits for accurate estimation.

Abbreviations: CI, confidence interval; DPP, dipeptidyl peptidase; GLP glucagon-like peptide; SGLT, sodium/glucose cotransporter.